Leyden Labs
Last verified 2026-05-25. JSON
The funding figures on this page are attributed, not sourced: a publisher is on record but no document URL is. How we mark provenance.
| Total raised | $73.4Mattributed |
|---|---|
| Latest round | series-b, $73.4M, 2025-01-01attributed |
| Founded | unknown |
| Headquarters | Leiden |
| Industry | bio |
| Stage | series-b+ |
| Website | leyden-labs.com |
Leyden Labs develops nasal sprays delivering antibodies to the respiratory mucosa to block flu, coronaviruses, and other viruses at entry. It targets at-risk groups, including the immunocompromised, and pandemic readiness. Its edge is its Mucosal Protection Platform, where low-dose intranasal antibodies stay effective as viruses mutate.
Funding rounds
| Date | Round | Amount | Lead |
|---|---|---|---|
| 2025-01-01 | series-b | $73.4M | undisclosed |
Detected tech stack
unknown
Provenance
| Fact | Status | Basis |
|---|---|---|
| Series B, $73.4M | attributed | sifted named as publisher. No document URL on file. |
| Total raised $73.4M | attributed | sifted named as publisher. No document URL on file. |
| Company existence | self-reported | leyden-labs.com, read 2026-05-25 |
| Description | self-reported | leyden-labs.com, read 2026-05-25 |
Nothing on this page is sourced yet. A sourced fact links to a document that states it.
Change history
No change recorded since records began on 2026-09-24.